The order a fund closes bolt-ons in is a structuring decision, not a scheduling one. It decides which financing is available, and which governance framework each seller joins.
Key takeaways
A fund building a platform through repeated add-ons is running several clocks at once: how fast the sponsor's own diligence and integration team can absorb a new business, how the financing available to a deal changes as the group gets bigger, and how the governance structure holding earlier sellers together has to accommodate the next one. Sequencing those clocks deliberately, rather than acquiring opportunistically in whatever order deals surface, is what turns a series of one-off purchases into a programme.
In the first year, while the platform itself is thin on operating history, the Canada Small Business Financing Program (CSBFP) is usually the cheapest financing an add-on can draw on — but only if the deal is structured to qualify. ISED's own eligibility rule limits the programme to “small businesses or start-ups operating in Canada, with gross annual revenues of $10 million or less,” with a maximum loan amount for a borrower of $1.15 million, and its FAQ states plainly that the programme “cannot [be used] to finance items such as share purchases or assets that a holding company acquires.” That makes the early sequence self-selecting: the add-ons best suited to go first are the small, asset-purchase-eligible ones a participating lender can underwrite on CSBFP terms, not necessarily the largest or most strategic targets available. See the guide to applying for CSBFP funding for how a deal has to be shaped to qualify.
As the platform’s own scale grows, the financing available to later add-ons changes with it. Deavo puts it plainly: “Lenders underwrite micro deals on SDE and larger deals on EBITDA,” with the practical switch happening at roughly the $1 million mark. A sequencing plan should treat that as a real transition, not a footnote: once the group is financing acquisitions on an EBITDA basis through a commercial bank or BDC term loan, CSBFP is usually no longer the relevant programme, and it remains categorically unavailable for any add-on structured as a share purchase. If a later seller in the sequence needs a share sale for the lifetime capital gains exemption, that deal has to be financed with senior debt or seller financing instead — decide which trade-off the programme accepts before it reaches that seller’s negotiation, not during it. See choosing between a share deal and an asset deal for how that tension plays out on a single acquisition.
Where a seller wants to roll equity into the platform rather than cash out entirely, the usual mechanism is a joint election under ITA s.85(1), which lets the rollover happen on a tax-deferred basis where consideration includes shares of the acquiring corporation. Each rollover seller then becomes a minority shareholder in the platform, and the platform’s governance needs to say, in advance, what that shareholder can and cannot control. A unanimous shareholder agreement under CBCA s.146 is the standard tool: subsection (1) confirms an agreement “among all the shareholders” restricting the directors’ powers “is valid,” and subsection (3) provides that “a purchaser or transferee of shares subject to a unanimous shareholder agreement is deemed to be a party” to it automatically. Executing that agreement once, at platform formation, means every later rollover seller joins the same framework rather than renegotiating control from scratch — and it avoids the trap in subsection (4): a purchaser who was not given proper notice of the USA “may, no later than 30 days after they become aware” of it, rescind the transaction entirely.
Corporate consolidation is a separate, later-stage step, and the timing matters. CBCA s.184 allows wholly-owned subsidiaries of the same holding body corporate to amalgamate “without complying with sections 182 and 183” — no shareholder vote and no amalgamation agreement. That is genuinely useful once an add-on has been integrated and its risk profile is understood, folding it into a single operating entity rather than carrying a growing list of subsidiaries. Using it immediately on an unproven, just-closed add-on gives up the liability separation a fresh subsidiary provides during the period when an acquisition is most likely to surface a problem the diligence missed.
Nothing about sequence size changes the Competition Act’s criminal wage-fixing and no-poach rule. Section 45(1.1) makes it an offence for “every person who is an employer” who, with another unaffiliated employer, agrees “to not solicit or hire each other’s employees” — with no dollar threshold anywhere in the provision. The penalty in s.45(2) is indictable: “imprisonment for a term not exceeding 14 years.” The ancillary restraints defence in s.45(4) protects a non-solicit only where it “is ancillary to a broader or separate agreement” and “directly related to and reasonably necessary” for it — which means an informal understanding between the platform and a still-independent target, reached before any definitive agreement exists to be ancillary to, gets no protection at all. Any non-solicit or non-poach protection has to be drafted into the signed purchase agreement at the point a deal actually enters the sequence, never negotiated as a handshake earlier in the pipeline while the target is still a prospect.
Year one: the platform closes two small trades add-ons as asset purchases, $700,000 and $850,000, both financed in part through CSBFP loans within the $1.15 million per-borrower cap. Mid-year, the sponsor and the two sellers who kept minority equity execute a unanimous shareholder agreement governing the platform, so the framework already exists before a third seller joins. Year two is deliberately quiet on new acquisitions — integration only — and closes with the first short-form amalgamation under s.184, folding the two Year-one subsidiaries into a single operating entity now that both have a clean year of results behind them. Year three brings a $4.2 million professional-services add-on where the seller wants a share sale for the lifetime capital gains exemption; CSBFP is off the table by definition, so the deal is financed with a vendor take-back and a senior term loan underwritten on the group’s now-EBITDA-scale numbers instead.
Nothing in the sourced material prevents it, but each one still needs its own financing structure confirmed independently -- a CSBFP loan approval on one deal does not carry over to a second, and the $1.15 million cap applies per borrower, not per platform.
Yes, and that is exactly where it is riskiest. Section 45(1.1) has no closing-date trigger -- an informal no-poach understanding reached while a target is still a prospect gets no ancillary-restraints protection, because there is no signed broader agreement for the restraint to be ancillary to.
Only once the group's own aggregate assets or Canadian revenue, across the platform and all its affiliates, approaches the party-size threshold in s.109(1) -- $400 million. Most SME-scale sequencing plans never reach it, but a mature, multi-year roll-up should check the aggregate figure periodically rather than assume each new add-on is too small to count.
A 30-minute call is enough to tell you whether AI pays for itself here.
Nobody publishes Canadian transaction data, so every valuation in this country quotes an American benchmark. We are building the Canadian one — multiples, asking-to-sale spreads and days on market, by sector and by city. Leave an email and you will see it first.
No pitch, no listings. One email when the first report lands.
